Irritable Bowel Syndrome (IBS) Diagnostics Market to Grow at a CAGR of 5.9% to reach US$ 3,880.91 million from 2020 to 2028

Irritable bowel syndrome (IBS) diagnostics market was valued at US$ 2,470.61 million in 2020 and is projected to reach US$ 3,880.91 million by 2028; it is expected to grow at a CAGR of 5.9% from 2021 to 2028.

Irritable bowel syndrome (IBS) is defined as a gastro-intestinal disorder causing discomfort in the stomach, along with diarrhea, and constipation. IBS can develop after a severe session of diarrhea (gastroenteritis) caused by bacteria or a virus. IBS might also be associated with a surplus of bacteria in the bowels (bacterial overgrowth). People exposed to stressful events, especially in childhood, tend to have more symptoms of IBS. IBS diagnostics is done through medical history, physical exam, and imaging tests. However, IBS is majorly diagnosed by lactose intolerance tests, breath test for bacterial overgrowth, blood test, and stool test. The tests are done based on symptoms such as constipation-predominant, diarrhea-predominant, or mixed. It can also detect by various imaging tests such as CT Scan or X-ray, upper endoscopy, and colonoscopy.

Irritable bowel syndrome (IBS) diagnostics market is segmented on the basis of diagnosis, indication, and geography. By geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the irritable bowel syndrome (IBS) diagnostics market, emphasizing on parameters such as market trends, technological advancements, and market dynamics along with the analysis of competitive landscape of world’s leading market players.    

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Irritable Bowel Syndrome (IBS) Diagnostics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights

Irritable bowel syndrome is a chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. The disease is also known as spastic colon, irritable colon, mucous colitis, and spastic colitis. Irritable bowel syndrome shows symptoms such as abdominal pain, constipation, diarrhea, and cramping.

People across the world are witnessing considerable incidence of irritable bowel syndrome. According to the data published by International Foundation for Gastrointestinal Disorders, among all irritable bowel syndrome patients, about 40% of people have mild IBS, around 35% have moderate IBS, and an estimated 25% have severe IBS. Food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. According to a study published on NCBI in 2018, irritable bowel syndrome is estimated to affect around 10–16% of the US population each year. Further, as per the IBS Global Impact Report, in 2016, an estimated mean prevalence of individual countries ranged from 1.1% in France and Iran to 35.5% in Mexico. Latin America had a prevalence rate of 17.5%, Asia 9.6%, North America/Europe/Australia/New Zealand 7.1%, and the Middle East & Africa had a prevalence rate of 5.8%.  Such staggering prevalence of irritable bowel syndrome is likely to boost the irritable bowel syndrome (IBS) diagnostics market during the forecast period.

To cope up against irritable bowel syndrome, the market players are taking constructive steps to create programs to spread awareness among the population. For instance, in 2018, the collaboration of Allergan PLC and Ironwood launched an Interactive Digital Destination platform to encourage sufferers to get educated and act. Similarly, in January 2018, Commonwealth Diagnostics International, Inc. collaborated with American professional golfer, Rob Oppenheim to raise awareness about irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).

Increasing Number of FDA Approvals and Diagnostics Developments Contribute Significantly to Market Growth

Increasing number of FDA approvals and diagnostics development activities are likely to accelerate the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period. Majority of the established as well as new players are coming forward to develop and manufacture diagnostic solutions for the disease, which will lead to ample availability of the diagnostic solutions in the market. For instance, in February 2020, Commonwealth Diagnostics International (CDI), Inc. re-launched the IBSchek, the first clinically validated biomarker blood test for mixed-type irritable bowel syndrome (IBS-D, IBS-M) and diarrhea-predominant in a new at-home capillary collection kit. Further, in October 2018, Gemelli Biotech launched the IBS-smart, an innovation in blood testing for irritable bowel syndrome (IBS), in partnership with Medically Associated Science and Technology Program (MAST) at Cedars-Sinai.

The irritable bowel syndrome (IBS) diagnostics market is projected to witness approvals of diagnostic solutions, which will eventually have a positive impact on the growth of the market. For instance, in June 2019, BÜHLMANN Laboratories AG received United States Food and Drug Administration (FDA) 510(k) clearance for its BÜHLMANN fCAL turbo Automated Calprotectin Test and BÜHLMANN fCAL ELISA Calprotectin Test. According to company estimates, the test is anticipated to observe thriving sales in the global market.

Diagnosis Insights            

Based on diagnosis, the global irritable bowel syndrome (IBS) diagnostics market is segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held the largest share in the market. Moreover, the segment is expected to hold the largest market share by 2028. The market growth is mainly attributed to the growing prevalence of irritable bowel syndrome (IBS) worldwide, which is likely to continue in the coming years due to disturbances in bowel habits and abdominal pain. This, in turn, is boosting the demand for diagnosis of these diseases worldwide.

Indication Insights

Based on indication, the global irritable bowel syndrome (IBS) diagnostics market is segmented into pain and cramping, diarrhea, constipation, and alternating constipation and diarrhea. The pain and cramping segment held the largest market share in 2020, and it is further expected to dominate the market by 2028. Antispasmodics and antidepressants are medication used to treat IBS pain and cramping.    

Product launches, and mergers and acquisitions are highly adopted strategies in the global irritable bowel syndrome (IBS) diagnostics market. A few of the recent key product developments are listed below:

In February 2020, Commonwealth Diagnostics International (CDI), Inc., announced the commercial re-launch of IBSchek, the first clinically validated biomarker blood test for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D, IBS-M) in a new at-home capillary collection kit.

In January 2019, Gemelli Biotech announced a partnership with Kuwait-based Advanced Medical German Co. (AMG), one of the leading international distributors of medical products and services in the Middle East. Through the partnership, AMG will distribute Gemelli's proprietary diagnostic blood test for IBS, ibs-smart, in major territories in the Middle East and North Africa, including Kuwait, the UAE, Qatar, Saudi Arabia, Egypt, and Turkey.

The COVID-19 pandemic is estimated to have a significant positive impact on the irritable bowel syndrome (IBS) diagnostics market. Majority of the pharmaceutical companies across the world are engaged in the development of vaccines for COVID-19. Moreover, irritable bowel syndrome (IBS) is frequently triggered by COVID-19 stress. Thus, home testing kits are preferable to laboratory testing as laboratory services may be overwhelmed in the pandemic, which is anticipated to have a positive impact on the other segments of the market in the coming months. However, disruptions in the supply chain caused due to the halt in global operations are hindering the market growth. 

Irritable Bowel Syndrome (IBS) Diagnostics Market Regional Insights

The regional trends and factors influencing the Irritable Bowel Syndrome (IBS) Diagnostics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Irritable Bowel Syndrome (IBS) Diagnostics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Irritable Bowel Syndrome (IBS) Diagnostics Market Report Scope

Irritable Bowel Syndrome (IBS) Diagnostics Market Players Density: Understanding Its Impact on Business Dynamics

The Irritable Bowel Syndrome (IBS) Diagnostics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Irritable Bowel Syndrome (IBS) Diagnostics Market are:

1. Commonwealth Diagnostics International
2. Genova Diagnostics
3. Gemelli Biotech
4. Prometheus Laboratories
5. Inova Diagnostics, Inc.

Disclaimer: The companies listed above are not ranked in any particular order.

Irritable Bowel Syndrome (IBS) Diagnostics – Market Segmentation

By Diagnosis

• Laboratory Tests
  • Lactose Intolerance Tests
  • Breath Test for Bacterial Overgrowth
  • Stool Tests
  • Blood Tests
• Imaging Tests
  • CT Scan or X-Ray
  • Upper Endoscopy
  • Colonoscopy

By Indication

• Pain and Cramping
• Diarrhea
• Constipation
• Alternating Constipation and Diarrhea

By Geography

• North America

  • US
  • Canada
  • Mexico

• Europe

  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe

• Asia Pacific (APAC)

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

• Middle East & Africa (MEA)

  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa

• South and Central America (SCAM)

  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• Commonwealth Diagnostics International
• Genova Diagnostics
• Gemelli Biotech
• Prometheus Laboratories
• Inova Diagnostics, Inc.
• Biohit Oyj
• Aerodiagnostics, LLC.
• Metabolic Solutions, Inc.
• Sysmex Corporation
• Bühlmann Laboratories AG